Genocea commercializes key breakthroughs in vaccine discovery and development. The company was founded by Lux and spun-out from Harvard Medical School. The company completed its IPO in 2014.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases. Traditional discovery methods have proven unable to identify the targets of immune response. ATLAS, Genocea's proprietary technology platform, mimics the human immune system to identify the targets most likely to illicit an immune response. Genocea's pipeline of novel, clinical-stage, T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for pneumococcus, and earlier-stage programs in chlamydia, malaria and cancer immunotherapy.
- Kevin Bitterman
- Darren Higgins
- Robert Paull
- David Sinclair
- Larry Bock
- Only ATLAS™ can identify inhibitory antigens or Inhibigens™ that suppress anti-tumor responses. These findings cont… https://t.co/oemzkIFhnm
- Happening today! Join us at @KeystoneSymp, where Genocea’s scientist, @hannastarobin, will reveal more about how re… https://t.co/3PYS1yPYVU
- Want to learn how our GEN-011 neoantigen cell therapy builds upon the current limitations of TIL & TCR-T therapies?… https://t.co/NPHYvVgFGJ